Complete

Developing a delivery system to improve treatment for aggressive breast cancer

Cancer types:

Breast cancer

Project period:

Research institute:

National Research Council of Italy (ISOF-CNR)

Award amount:

£123,776

Location:

Italy

Researcher Dr Greta Varchi

Dr Greta Varchi and her team are trying to improve the treatment of triple-negative breast cancer by designing a new way of delivering drugs to the tumour. 

Hope for the future

Triple-negative breast cancer is the most aggressive type of breast cancer and is more common in people under the age of 40. Over 8,000 people are diagnosed with triple-negative breast cancer in the UK every year and effective and targeted therapies are still lacking. Just over 6 in 10 people with triple-negative breast cancer survive for five years or more, trailing behind the average for all breast cancers of more than 8 in 10 people. 

Dr Varchi and her team are now developing a highly innovative way to deliver treatments directly to the tumour to improve survival rates. They hope that their new treatment strategy could also be applied to other types of cancer in the future. 

Meet the scientist

Dr Greta Varchi packs her time away from the lab with travelling around Italy and Europe (including two pilgrimages of the “Camino de Santiago), running (marathons!), favourite movies (Notting Hill), reading (at least 1 hour a day) and experimenting in the kitchen (Tortellini, Lasagne, Ragù). She also points out that “one of my favourite hobbies is my job! I feel I have the most beautiful job in the world”. 

The science

Triple-negative breast cancer does not rely on oestrogen, progesterone or HER2 protein to grow, which can make it difficult to treat. Recent evidence suggests that a combination of chemotherapy and immunotherapy might be a way forward, but it remains unclear how to best deliver the drugs to the tumour without causing too many side effects. 

Dr Greta Varchi and her team are now investigating a way to deliver the drugs directly to the tumour by exploiting certain cancer cell characteristics. They are developing a new “nano-system” onto which both drugs can be loaded. The nano-system then releases the two drugs only under the specific conditions which are present at the tumour site. By delivering the drugs directly to the tumour, Dr Varchi and her team hope to reduce side effects, while improving the effectiveness of the treatment. 

Without your support, this research would not be possible. I will do my best to deserve your trust and achieve the results that I planned to achieve. I do not know you in person, but I think of you when I do my job.

Dr Greta Varchi

Related projects

Anne Vincent Salomon Headshot

Complete France

Breast cancer

Can AI predict which patients will become resistant to treatment?

Researchers hope to find better, more personalised treatments for breast cancer patients by identifying characteristics that predict how a tumour will behave.

Researcher: Dr Anne Vincent-Salomon

Using AI to predict drug resistance mutations in breast cancer
Aura Carreira Headshot

Active Spain

Breast cancer

How does a faulty BRCA2 gene cause breast cancer to develop?

The team hope that by understanding how different mutations contribute to breast cancer, they can reveal new ways to prevent, diagnose and treat it.  

Researcher: Dr Aura Carreira

Uncovering how a faulty BRCA2 gene causes breast cancer to develop
Staffan Stromblad Team Shot

Active Sweden

Multiple cancers

How does ‘tissue stiffening’ affect cancer development?

This project hopes to discover more about the biology of how solid tumours develop to find new ways to prevent, diagnose or treat these cancers.

Researcher: Professor Staffan Stromblad

Understanding how 'tissue stiffening' affects cancer development
Share this page